Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 4

Urology Times

“This represents one of the largest reported in the phase 3 trials in first-line mCRPC,” says investigator Noel W. Clarke, MBBS, FRCS, ChM.

  • 123456 Profile photo of Madelyn

    I disagree with the headline but looks like this is the link that is postable. Final overall survival data for PROpel – (abi + olaparib in first line mCRPC). Not fully mature, trend towards improvement, greatest in patients with BRCA mutated disease with almost no difference in the patients with non BRCA mutated disease.